文献速递妇科肿瘤

妇科恶性肿瘤新兴治疗靶点与早期药物开发

Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies.
PubMed 文献 · Ann Oncol · 2026-10-14

妇科恶性肿瘤仍是癌症相关发病和死亡的主要原因,尤其在复发和难治性情况下。分子分析进展加速了生物标志物驱动疗法的开发,拓展了传统化疗和第一代靶向药之外的选项。本综述重点介绍妇科癌症靶向与免疫治疗的最新进展,并讨论生物标志物驱动药物开发与治疗序贯的未来方向。

要点

  • 靶向DNA损伤应答通路(WEE1、PKMYT1、WRN)及CCNE1扩增、TP53 Y220C等变异显示鼓舞性临床活性。
  • 抗体药物偶联物已成为主要治疗类别。
  • 免疫治疗从免疫检查点抑制剂拓展至双特异性抗体、T细胞衔接器、工程化TCR和CAR-T细胞。

核心结论

  • 妇科恶性肿瘤的靶向与免疫治疗正快速发展,生物标志物驱动策略拓展了治疗选择。

研究设计与样本

  • 综述,聚焦妇科恶性肿瘤新兴治疗靶点与早期药物开发。

主要发现

  • 靶向WEE1、PKMYT1、WRN的DNA损伤应答通路策略及CCNE1扩增、TP53 Y220C等可操作变异显示鼓舞性临床活性。
  • 抗体药物偶联物已成为主要治疗类别。
  • 免疫治疗从免疫检查点抑制剂拓展至双特异性抗体、T细胞衔接器、工程化T细胞受体疗法和CAR-T细胞。

局限性

  • 肿瘤异质性、生物标志物复杂性和获得性耐药仍是主要挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gynecological malignancies remain a major cause of cancer-related morbidity and mortality, particularly in recurrent and treatment-resistant settings. Advances in molecular profiling have accelerated the development of biomarker-driven therapies, expanding treatment options beyond conventional chemotherapy and first-generation targeted agents. Novel strategies targeting DNA damage response pathways, including WEE1, PKMYT1, and WRN, as well as vulnerabilities associated with CCNE1 amplification and actionable alterations such as TP53 Y220C, are showing encouraging clinical activity. Antibody-drug conjugates have emerged as a major therapeutic class, while immunotherapeutic approaches are evolving beyond immune checkpoint inhibitors to include bispecific antibodies, T-cell engagers, engineered T-cell receptor therapies, and CAR-T cells. Despite these advances, tumor heterogeneity, biomarker complexity, and acquired resistance remain major challenges. This review highlights recent developments in targeted and immune-based therapies across gynecological cancers and discusses future directions for biomarker-driven drug development and therapeutic sequencing.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ouali K, Tan D, Lheureux S, et al. Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies. Ann Oncol. 2026. PMID: 42874919. doi:10.1016/j.annonc.2026.10.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。